MSS
Showing 26 - 50 of 920
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma Trial in Baltimore (Nivolumab, Relatlimab)
Recruiting
- Microsatellite Stable (MSS) Colorectal Adenocarcinomas
- Colorectal Adenocarcinoma
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Mar 14, 2022
Locally Advanced Rectal Cancer Trial in Guangzhou (AK104, Capecitabine, Neoadjuvant Radiotherapy)
Not yet recruiting
- Locally Advanced Rectal Cancer
- AK104
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 5, 2023
Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)
Not yet recruiting
- Rectal Cancer
- Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
- (no location specified)
Aug 29, 2023
Metastatic Colorectal Cancer, MSS Trial in Heidelberg (Pembrolizumab, Maraviroc)
Completed
- Metastatic Colorectal Cancer
- MSS
- Pembrolizumab
- Maraviroc
-
Heidelberg, GermanyNational Center for Tumor Diseases, University Hospital Heidelbe
May 17, 2022
Melanoma Trial in New Brunswick (MSS enhancement, Educational webpage on SSE, Assess implementation outcomes)
Not yet recruiting
- Melanoma
- MSS enhancement
- +2 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Oct 17, 2022
Malignant Tumors of Digestive Organs, Colorectal Cancer, Colon Cancer Trial in Houston (Durvalumab, Trametinib)
Completed
- Malignant Neoplasms of Digestive Organs
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
May 23, 2022
Colorectal Tumors Trial in Xiamen (hypofractionation Radiotherapy, sintilimab, GM-CSF)
Recruiting
- Colorectal Neoplasms
- hypofractionation Radiotherapy
- +3 more
-
Xiamen, Fujian, ChinaThe First Affiliated Hospital of Xiamen University
Mar 28, 2022
Colorectal Cancer, Liver Metastases Trial in Hangzhou (Experimental drug)
Recruiting
- Colorectal Cancer
- Liver Metastases
- Experimental drug
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital, Zhejiang University School of Me
Jun 5, 2022
Colorectal Cancer Trial in Harbin (AK119, AK112, Oxaliplatin)
Not yet recruiting
- Colorectal Cancer
- AK119
- +5 more
-
Harbin, ChinaCancer Hospital Affiliated to Harbin Medical University
May 5, 2023
Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma Trial in Trondheim, Lørenskog, Oslo
Not yet recruiting
- Colorectal Adenocarcinoma
- +2 more
-
Trondheim, Trondelag, Norway
- +2 more
Aug 15, 2022
Metastatic Colorectal Cancer Trial in Providence (Dose level 1 ONC201 625mg, Dose level 2 ONC201 500mg, Dose level 3 ONC201
Terminated
- Metastatic Colorectal Cancer
- Dose level 1 ONC201 625mg
- +2 more
-
Providence, Rhode IslandLifespan Cancer Institute: The Miriam and Rhode Island Hospitals
May 25, 2022
CCR5, Microsatellite Stable, Metastatic Trial (700mg leronlimab weekly dose, 80mg Regorafenib at week 1, 120mg Regorafenib at
Withdrawn
- CCR5
- +3 more
- 700mg leronlimab weekly dose
- +3 more
- (no location specified)
Feb 15, 2023
Mismatch Repair-proficient, Colorectal Cancer Metastatic, Microsatellite Stable Trial in Hangzhou (Tislelizumab, Irinotecan,
Recruiting
- Mismatch Repair-proficient
- +2 more
- Tislelizumab
- +2 more
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Dec 17, 2021
Metastatic Microsatellite-stable Colorectal Cancer Trial in China (Experimental drug, Control Rx)
Recruiting
- Metastatic Microsatellite-stable Colorectal Cancer
- Experimental drug
- Control Rx
-
Hefei, Anhui, China
- +11 more
Mar 13, 2023
Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant
Not yet recruiting
- Multiple Cancer
- Colorectal Cancer
- MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
- All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
- (no location specified)
Aug 20, 2023
NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma Trial in Pittsburgh (Pixatimod, Nivolumab, Cyclophosphamide (low
Recruiting
- NSCLC
- +2 more
- Pixatimod
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Mar 28, 2022
Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma Trial in
Active, not recruiting
- Colorectal Adenocarcinoma
- +7 more
- Metformin
- Nivolumab
-
Atlanta, Georgia
- +2 more
May 6, 2022
MSS, pMMR, Metastatic Colorectal Adenocarcinoma Trial in Shenyang (TKI ± anti-PD-1 antibody)
Recruiting
- MSS
- +2 more
- TKI ± anti-PD-1 antibody
-
Shenyang, Liaoning, ChinaCancer Hospital of China Medical University/Liaoning Cancer Hosp
Sep 28, 2021
Rectum Cancer, Rectal Cancer Trial in Geneva (Pembrolizumab)
Recruiting
- Rectum Cancer
- Rectal Cancer
-
Geneva, SwitzerlandHôpitaux Universitaires de Genève
Sep 29, 2021
Pancreatic Cancer, Metastatic Pancreatic Cancer Trial in Boston (Nivolumab, Ipilimumab, Radiation)
Active, not recruiting
- Pancreatic Cancer
- Metastatic Pancreatic Cancer
- Nivolumab
- +2 more
-
Boston, Massachusetts
- +2 more
Sep 7, 2022
Rectal Cancer, Locally Advanced Trial (radiation, drug, procedure)
Not yet recruiting
- Rectal Cancer
- Locally Advanced
- Short-course radiotherapy
- +3 more
- (no location specified)
Oct 8, 2022
Rectal Cancer, MSS Trial in Beijing (Cadonilimab, Oxaliplatin, Capecitabine)
Recruiting
- Rectal Cancer
- MSS
- Cadonilimab
- +2 more
-
Beijing, Beijing, ChinaNational Cancer Center/Cancer Hospital, Chinese Academy of Medic
Apr 13, 2023
Microsatellite Stable Colorectal Cancer Trial in United States (grapiprant, grapiprant and pembrolizumab)
Active, not recruiting
- Microsatellite Stable Colorectal Cancer
- grapiprant
- grapiprant and pembrolizumab
-
Phoenix, Arizona
- +3 more
Apr 21, 2022